<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30157918</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>19</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1756-9966</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>37</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of experimental &amp; clinical cancer research : CR</Title>                <ISOAbbreviation>J. Exp. Clin. Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.</ArticleTitle>            <Pagination>                <MedlinePgn>202</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13046-018-0875-3</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Resistance to trastuzumab has become a leading cause of mortality in breast cancer patients and is one of the major obstacles for improving the clinical outcome. Cell behavior can be modulated by long non-coding RNAs (lncRNAs), but the contribution of lncRNAs in trastuzumab resistance to breast cancer is largely unknown. To this end, the involvement and regulatory function of lncRNA AGAP2-AS1 in human breast cancer are yet to be investigated.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Trastuzumab-resistant SKBR-3 and BT474 cells were obtained by continuous culture with 5 mg/mL trastuzumab for 6 months. RT-qPCR assay was used to determine the expression of AGAP2-AS1 in tissues and cells. RNA fluorescence in situ hybridization was used to investigate the subcellular location of AGAP2-AS1 in breast cancer cells. Bioinformatic analysis, chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), western blotting, and immunofluorescence were carried out to verify the regulatory interaction of AGAP2-AS1, CREB-binding protein (CBP), and MyD88. In addition, a series of in vitro assays and a xenograft tumor model were used to analyze the functions of AGAP2-AS1 in breast cancer cells.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">AGAP2-AS1 was upregulated and transcriptionally induced by SP1 in breast cancer. Overexpression of AGAP2-AS1 promoted cell growth, suppressed apoptosis, and caused trastuzumab resistance, whereas knockdown of AGAP2-AS1 showed an opposite effect. MyD88 was identified as a downstream target of AGAP2-AS1 and mediated the AGAP2-AS1-induced oncogenic effects. Mechanistically, the RIP assay revealed that AGAP2-AS1 could bind to CBP, a transcriptional co-activator. ChIP assays showed that AGAP2-AS1-bound CBP increased the enrichment of H3K27ac at the promoter region of MyD88, thus resulting in the upregulation of MyD88. Gain- and loss-of-function assays confirmed that the NF-κB pathway was activated by MyD88 and AGAP2-AS1. Furthermore, high AGAP2-AS1 expression was associated with poor clinical response to trastuzumab therapy in breast cancer patients.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AGAP2-AS1 could promote breast cancer growth and trastuzumab resistance by activating the NF-κB signaling pathway and upregulating MyD88 expression. Therefore, AGAP2-AS1 may serve as a novel biomarker for prognosis and act as a therapeutic target for the trastuzumab treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Dong</LastName>                    <ForeName>Huaying</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China. dr_dhy@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mo</LastName>                    <ForeName>Shaowei</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Science and Education, Hainan Maternal and Child health hospital, Haikou, 570206, Hainan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Ru</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zou</LastName>                    <ForeName>Kejian</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Jing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Fan</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery, Hainan General Hospital, Jinan University, No.19 Xiu Hua Road, Xiuying District, Haikou city, 570311, Hainan Province, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Jianguo</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>02A2150014P1</GrantID>                    <Agency>Hainan provincial health fund</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Exp Clin Cancer Res</MedlineTA>            <NlmUniqueID>8308647</NlmUniqueID>            <ISSNLinking>0392-9078</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C507779">MYD88 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C108209">Sp1 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C000625008">long non-coding RNA AGAP2-AS1, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P188ANX8CK</RegistryNumber>                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2014 Nov 20;159(5):1110-1125</RefSource>                <PMID Version="1">25416949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Ther. 2014 Jul-Sep;10(3):506-11</RefSource>                <PMID Version="1">25313729</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2014 Sep 15;135(6):1356-68</RefSource>                <PMID Version="1">24615544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Immunol. 2014 Jul 31;5:367</RefSource>                <PMID Version="1">25132836</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2011 Sep 16;43(6):904-14</RefSource>                <PMID Version="1">21925379</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Dev. 2009 Jul 1;23(13):1494-504</RefSource>                <PMID Version="1">19571179</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Exp Med Biol. 2007;608:1-22</RefSource>                <PMID Version="1">17993229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Clin Invest. 2009 Feb;39(2):157-64</RefSource>                <PMID Version="1">19200169</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2009 Apr;9(4):265-73</RefSource>                <PMID Version="1">19262571</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Jan 1;25(1):118-45</RefSource>                <PMID Version="1">17159189</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2014 Oct;35(10):2346-56</RefSource>                <PMID Version="1">25085904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2015 May 7;161(4):774-89</RefSource>                <PMID Version="1">25957685</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2011 Feb 2;31(5):1652-63</RefSource>                <PMID Version="1">21289174</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2009 Mar 15;69(6):2191-4</RefSource>                <PMID Version="1">19276389</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2010;12(6):R99</RefSource>                <PMID Version="1">21092082</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2017 Oct 12;8(10):e3124</RefSource>                <PMID Version="1">29022910</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 Mar 2;102(5):908-15</RefSource>                <PMID Version="1">20145615</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2012 Apr;19(4):722-31</RefSource>                <PMID Version="1">22158417</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Feb 26;14:134</RefSource>                <PMID Version="1">24571711</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2010 Sep 29;30(39):13066-77</RefSource>                <PMID Version="1">20881124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2014 Oct 9;159(2):458-458.e1</RefSource>                <PMID Version="1">25303536</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2008 May 16;133(4):704-15</RefSource>                <PMID Version="1">18485877</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Rev Med Pharmacol Sci. 2017 May;21(10):2392-2396</RefSource>                <PMID Version="1">28617550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2017 Jan 12;168(1-2):135-149.e22</RefSource>                <PMID Version="1">28086087</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2007 Feb 23;128(4):693-705</RefSource>                <PMID Version="1">17320507</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>                <PMID Version="1">19097774</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Oncol. 2012 Jun 18;2:62</RefSource>                <PMID Version="1">22720269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol. 2014 Oct;38(5):556-62</RefSource>                <PMID Version="1">25172158</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Immunol. 2009 Aug;9(8):581-93</RefSource>                <PMID Version="1">19498381</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Immunol. 2009 Sep;46(15):2876-84</RefSource>                <PMID Version="1">19643479</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2016 May 19;7:e2225</RefSource>                <PMID Version="1">27195672</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Immunol. 2012;272(2):220-9</RefSource>                <PMID Version="1">22088941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 May 10;6(13):11652-63</RefSource>                <PMID Version="1">25871474</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Jun;127(2):471-8</RefSource>                <PMID Version="1">20957431</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2000 Dec 11;19(53):6115-21</RefSource>                <PMID Version="1">11156524</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hematol Oncol. 2017 Feb 16;10(1):48</RefSource>                <PMID Version="1">28209205</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Nov;14(12):1183-92</RefSource>                <PMID Version="1">24095300</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2011 May 27;286(21):19127-37</RefSource>                <PMID Version="1">21471222</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Genet. 2009 Mar;10(3):155-9</RefSource>                <PMID Version="1">19188922</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053594" MajorTopicYN="N">Myeloid Differentiation Factor 88</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">H3K27 acetylation</Keyword>            <Keyword MajorTopicYN="N">MyD88</Keyword>            <Keyword MajorTopicYN="N">SP1</Keyword>            <Keyword MajorTopicYN="N">Trastuzumab</Keyword>            <Keyword MajorTopicYN="N">lncRNA AGAP2-AS1</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30157918</ArticleId>            <ArticleId IdType="doi">10.1186/s13046-018-0875-3</ArticleId>            <ArticleId IdType="pii">10.1186/s13046-018-0875-3</ArticleId>            <ArticleId IdType="pmc">PMC6114182</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>